Medical technology company Becton, Dickinson and Company (NYSE: BDX) will be reporting results tomorrow before market open. Here’s what to look for.
BD beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $5.17 billion, up 9.8% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ EPS estimates and an impressive beat of analysts’ constant currency revenue estimates.
Is BD a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting BD’s revenue to grow 6.1% year on year to $5.35 billion, improving from the 4.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.28 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BD has missed Wall Street’s revenue estimates twice over the last two years.
Looking at BD’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 2.7%, and Boston Scientific reported revenues up 20.9%, topping estimates by 2%. Penumbra traded up 7.2% following the results while Boston Scientific was also up 6.5%.
Read our full analysis of Penumbra’s results here and Boston Scientific’s results here.
The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. BD is down 8.7% during the same time and is heading into earnings with an average analyst price target of $273.70 (compared to the current share price of $206.44).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
